The administration of oral THC mitigates symptoms of post-traumatic stress syndrome (PTSD), according to clinical trial data published online ahead of print in the journal Clinical Drug Investigation.
Investigators at the Hebrew University Medical Center in Jerusalem assessed the safety and efficacy of oral THC as an adjunct treatment in ten subjects with chronic PTSD.
Researchers reported, “The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.”
They concluded, “Orally absorbable delta-9-THC was safe and well tolerated by patients with chronic PTSD.”
Separate clinical trial data has previously reported that the administration of nabilone, a synthetic endocannabinoid agonist, can reduce the severity and frequency of nightmares in patients with PTSD.
Tag Archives | THC
Just in time for 4/20: Reality Sandwich’s Alan Badiner writes about the presence of naturally-occurring endocannabinoids in the food supply:
… Read the rest
Aside from the cannabinoids produced by the body and those found in cannabis, there are numerous substances that interact with the endocannabinoid system, such as cacao, black pepper, echinacea, tumeric and even carrots. But it is the Cannabis plant that produces the most powerful cannabinoids mimicing most closely those produced by the body. No downsides, no side-effects, no drug interaction issues, and so far, no giving up your hard earned funds to big pharma.
Make no mistake, I’m not referring to THC, of which Americans smoke more of per person than any other people on Earth, but rather the “other,” non-psychoactive cannabinoid called Cannabidiol (CBD), a prominent molecular component of the cannabis plant. While CBD does not bind to either the CB1 or CB2 cannabinoid receptors directly, it does stimulate endogenous cannabinoid activity by suppressing an enzyme that breaks down anandamide.
If the hundreds of uses for cannabis doesn’t plead the case for its legalization, the money made from its medical industry just might do it. The Washington Independent reports:
… Read the rest
The American Independent has previously reported on the growing corporatization of the incipient medical marijuana industry at a time when medical marijuana dispensaries scrabble to hold on to their businesses in the face of a multi-pronged federal crackdown. But there are signs afoot that it just may become ever more corporate if a Big Pharma push to get the U.S. Food and Drug Administration to recognize a cannabis-derived drug is successful.
Last week, British prescription drug manufacturer GW Pharmaceuticals announced a licensing agreement with drug giant Novartis, maker of Ritalin and Excedrin, to begin selling GW’s drug Sativex in markets across Asia, Africa, Oceania and the Middle East. The medication is already available in Britain, where it’s produced and marketed by Bayer, and in Canada and Spain.
A really good graphic from the Wall Street Journal of all places!